Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact

Abstract

Influenza virus strain-specific monoclonal antibodies (mAbs) provide protection independent of Fc gamma receptor (FcγR) engagement. In contrast, optimal in vivo protection achieved by broadly reactive mAbs requires Fc-FcγR engagement. Most strain-specific mAbs target the head domain of the viral hemagglutinin (HA), whereas broadly reactive mAbs typically recognize epitopes within the HA stalk. This observation has led to questions regarding the mechanism regulating the activation of Fc-dependent effector functions by broadly reactive antibodies. To dissect the molecular mechanism responsible for this dichotomy, we inserted the FLAG epitope into discrete locations on HAs. By characterizing the interactions of several FLAG-tagged HAs with a FLAG-specific antibody, we show that in addition to Fc-FcγR engagement mediated by the FLAG-specific antibody, a second intermolecular bridge between the receptor-binding region of the HA and sialic acid on effector cells is required for optimal activation. Inhibition of this second molecular bridge, through the use of an F(ab′) 2 or the mutation of the sialic acid-binding site, renders the Fc-FcγR interaction unable to optimally activate effector cells. Our findings indicate that broadly reactive mAbs require two molecular contacts to possibly stabilize the immunologic synapse and potently induce antibody-dependent cell-mediated antiviral responses: (i) the interaction between the Fc of a mAb bound to HA with the FcγR of the effector cell and (ii) the interaction between the HA and its sialic acid receptor on the effector cell. This concept might be broadly applicable for protective antibody responses to viral pathogens that have suitable receptors on effector cells. hemagglutinin | influenza virus | antibody-dependent cell-mediated immunity | broadly reactive antibodies | Fcγ receptor

Inactivated influenza virus vaccines: the future of TIV and QIV

“…This is indeed observed for oil in water adjuvants that were tested with IIV in humans [40]. Antibody isotype class switching can be crucial for (universal) influenza vaccine types that rely on antibodies that require Fc receptor mediated mechanisms in order to provide protection, since different antibody subtypes can engage different Fc receptors on effector cells with different efficiencies [19–21]. Enhancing antibody responses with the use of adjuvants allows antigen dose sparing, which means less vaccine needs to be used in to induce a protective immune response.…”

Signaling by Antibodies: Recent Progress

“…In contrast, higher affinity IgGs are more likely to form bivalent interactions with antigen (1 Fc domain per 2 bound Fab domains), limiting the potential for dense IgG binding (117). ADCC mediated by broadly reactive anti-HA mAbs may also be supported through increased affinity between target and effector cell due to broadly neutralizing mAb Fc-FcγRIIIa engagement in conjunction with binding by the viral HA to sialic acids on the effector cell (118). Yet another mechanism that may impact the ability of a bound IgG to engage FcγRs is conformational change in the Fc domain induced upon binding of the Fab domain to antigen (119-121).…”

Immunological responses to influenza vaccination: lessons for improving vaccine efficacy

“…Studies showing the critical role of activating FcγRs in heterologous influenza immunity in vivo suggest that skewing the influenza vaccine antibody response away from IgG2 could significantly improve the breadth and potency of elicited IgGs [29,30,32]. This could potentially be done using adjuvants that have Th1-polarizing activity, such as those that trigger pattern-recognition receptors.…”